CD166, also known as activated leukocyte cell adhesion molecule (ALCAM), is a transmembrane glycoprotein that functions as a ligand for the CD6 molecule. CD166 belongs to the immunoglobulin superfamily and is broadly expressed on activated T cells, activated monocytes, epithelial cells, fibroblasts and neurons. CD166 has also been detected in melanoma and colorectal carcinoma as well as cancers of the breast, prostate and bladder. CD166 plays an important role in mediating adhesion interactions between thymic epithelial cells and CD6+ cells during T cell development in the thymus. Its expression can also be used as a prognostic marker for several cancers and as a potential cancer stem cell marker.
Anti-Human CD166 (3A6)-164Dy—100 Tests